| Keywords: |
immunohistochemistry; controlled study; protein expression; treatment outcome; unclassified drug; oncoprotein; androgen; pathogenesis; treatment planning; antineoplastic agents; drug targeting; ki 67 antigen; cell proliferation; ki-67 antigen; biological marker; prostate specific antigen; animals; in situ hybridization, fluorescence; gene overexpression; breast cancer; diagnosis, differential; epidermal growth factor receptor; epidermal growth factor receptor 2; cohort analysis; gene product; editorial; cytotoxicity; food and drug administration; protein tyrosine kinase; drug specificity; prostate cancer; prostate-specific antigen; prostatic neoplasms; health care cost; rna; gene expression regulation, neoplastic; basal cell; antibodies, monoclonal; fluorescence in situ hybridization; dna; disease progression; ligand; predictive value of tests; androgen receptor; receptor, erbb-2; orchiectomy; diagnostic test; up-regulation; tumor growth; molecular biology; trastuzumab; genes, erbb-2; cytological techniques; protein antibody; guanine nucleotide exchange factors; oncogene neu; cancer antibody; target organ; humans; human; male; priority journal
|
